116 aacr cancer Progress report 2015
findings from a national sample. Cancer Epidemiol
Biomarkers Prev 2015;24:969–77.
149. Stewart AF. Clinical practice. Hypercalcemia
associated with cancer. N Engl J Med 2005;352:373–9.
150. Hu MI, Glezerman IG, Leboulleux S, Insogna K,
Gucalp R, Misiorowski W, et al. Denosumab for
treatment of hypercalcemia of malignancy. J Clin
Endocrinol Metab 2014;99:3144–52.
151. Westmaas JL, Alcaraz KI, Berg CJ, Stein KD.
Prevalence and correlates of smoking and cessation-related behavior among survivors of ten cancers:
findings from a nationwide survey nine years after
diagnosis. Cancer Epidemiol Biomarkers Prev
152. Toll BA, Brandon TH, Gritz ER, Warren GW,
Herbst RS, AACR Subcommittee on Tobacco and
Cancer. Assessing tobacco use by cancer patients and
facilitating cessation: an American Association for
Cancer Research policy statement. Clin Cancer Res
153. Xu T, Zhu Z, Wang X, Xia L, Zhang X, Zhong S, et al.
Impact of body mass on recurrence and progression in
Chinese patients with Ta, T1 urothelial bladder cancer.
Int Urol Nephrol 2015;47:1135–41
154. Agalliu I, Williams S, Adler B, Androga L, Siev M,
Lin J, et al. The impact of obesity on prostate cancer
recurrence observed after exclusion of diabetics.
Cancer Causes Control 2015;26:821–30.
155. Kamineni A, Anderson ML, White E, Taplin SH,
Porter P, Ballard-Barbash R, et al. Body mass
index, tumor characteristics, and prognosis
following diagnosis of early-stage breast cancer in
a mammographically screened population. Cancer
Causes Control 2013;24:305–12.
156. Scarpa M, Ruffolo C, Erroi F, Fiorot A, Basato S, Pozza
A, et al. Obesity is a risk factor for multifocal disease
and recurrence after colorectal cancer surgery: a case-control study. Anticancer Res 2014;34:5735–41.
157. Betof AS, Dewhirst MW, Jones LW. Effects and
potential mechanisms of exercise training on cancer
progression: a translational perspective. Brain Behav
Immun 2013; 30 (Suppl):S75–87.
158. Brown JC, Schmitz KH. Weight lifting and physical
function among survivors of breast cancer: A post hoc
analysis of a randomized controlled trial. J Clin Oncol
159. Winters-Stone KM, Laudermilk M, Woo K, Brown JC,
Schmitz KH. Influence of weight training on skeletal
health of breast cancer survivors with or at risk for
breast cancer-related lymphedema. J Cancer Surviv
160. Deisseroth A, Kaminskas E, Grillo J, Chen W, Saber
H, Lu HL, et al. U.S. Food and Drug Administration
approval: ruxolitinib for the treatment of patients with
intermediate and high-risk myelofibrosis. Clin Cancer
161. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky
JM, Desrichard A, et al. Genetic basis for clinical
response to CTLA- 4 blockade in melanoma. N Engl
J Med 2014;371:2189–99.
162. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling
H, Eyring AD, et al. PD- 1 Blockade in tumors
with mismatch-repair deficiency. N Engl J Med
163. Thompson H. US National Cancer Institute’s new Ras
project targets an old foe. Nat Med 2013;19:949–50.
164. Stephen AG, Esposito D, Bagni RK, McCormick
F. Dragging ras back in the ring. Cancer Cell
165. Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn
KS, Bailey P, et al. Whole genomes redefine the
mutational landscape of pancreatic cancer. Nature
166. U.S. Food and Drug Administration. A framework
for FDA’s regulatory science initiative: Advancing
regulatory science for public health. 2010.
Available from: http://www.fda.gov/downloads/
167. Sawyers CL, van ‘t Veer LJ. Reliable and effective
diagnostics are keys to accelerating personalized
cancer medicine and transforming cancer care: a
policy statement from the american association for
cancer research. Clin Cancer Res 2014;20:4978–81.
168. Kulkarni S, Ma P. Personalized medicine: The path
forward. Palo Alto (CA): McKinsey and Company; 2013.
169. Perfetto EM, Burke L, Oehrlein EM, Epstein RS.
Patient-focused drug development: A new direction
for collaboration. Med Care 2015;53: 9–17.
170. National Institutes of Health. Our economy. 2014.
Available from: http://www.nih.gov/about/impact/
171. Kennedy JV, Atkinson RD. Healthy funding: Ensuring
a predictable and growing budget for the National
Institutes of Health. A report by United for Medical
Research and The Information Technology and
Innovation Foundation. 2015. Available from: http://
172. Federation of American Societies for Experimental
Biology. Federal funding for biomedical and related
life sciences research FY 2016. Bethesda (MD); 2015.
Available from: http://www.faseb.org/Portals/2/
173. Colditz GA. Carpe diem: Time to seize the
opportunity for cancer prevention. Am Soc Clin Oncol
Educ Book 2014: 8–12.